Painchek Ltd, a health care technology company based in Sydney, Australia, specializes in providing smartphone pain assessment and monitoring devices. These devices utilize facial recognition technology to detect pain, serving customers exclusively within Australia. The company’s offerings can be accessed through its website at www.painchek.com . Painchek’s stock is traded on the ASX All Markets.
As of January 28, 2026, Painchek has not reported any new corporate actions or earnings releases. The most recent publicly available news item, dated October 16, 2025, highlighted the company’s AI-powered facial-analysis app. This app is designed to detect subtle facial muscle movements, aiding clinicians in pain assessment.
Financially, Painchek’s stock closed at AUD 0.27 on January 27, 2026. Over the past 52 weeks, the stock has experienced significant volatility, trading between a low of AUD 0.245 on January 26, 2026, and a high of AUD 0.83 on October 7, 2025. The company’s market capitalization stands at AUD 55,386,936.
Painchek’s valuation multiples indicate a negative price-to-earnings ratio of -5.88 and a price-to-book ratio of -50.7059. These figures suggest that the company’s earnings and book value are below the current market price, reflecting challenges in achieving profitability. Despite these financial indicators, Painchek continues to focus on its innovative technology in the health care sector.
